Acumen raises $35.75M for EBD program, sabirnetug Phase 2 readout due late 2026
Acumen Pharmaceuticals ended 2025 with $116.9M in cash, equivalents and marketable securities, after a $35.75M private placement to advance its AβO-selective EBD candidates. Topline Phase 2 ALTITUDE-AD results for sabirnetug are expected late 2026, with an IND filing targeted mid-2027.
1. Year-end 2025 Financial Results
Acumen closed 2025 with $116.9 million in cash, equivalents and marketable securities, down from $136.1 million at September 2025, funding operations into early 2027. R&D expenses rose to $104.9 million, G&A expenses were $18.9 million, and net loss totaled $121.3 million.
2. Phase 2 ALTITUDE-AD Study Update
The company dosed the first patient in the open-label extension of its Phase 2 ALTITUDE-AD trial evaluating sabirnetug in early Alzheimer's patients. Topline results from the 18-month placebo-controlled study are expected in late 2026 to inform the role of toxic Aβ oligomers.
3. Enhanced Brain Delivery Program and Financing
Acumen secured $35.75 million in a private placement to advance its AβO-selective EBD candidates, which demonstrated up to 40-fold increased brain exposure in non-human primates. A lead clinical candidate IND filing is targeted for mid-2027 following strong preclinical safety and stability data.